Chimeric Antigen Receptor T-cell therapy
Chimeric antigen receptor T-cell therapy is an adoptive cellular immunotherapy in which a patient’s T cells are collected, commonly by leukapheresis, and genetically modified to express a chimeric antigen receptor (CAR).
Chimeric antigen receptor T-cell therapy is an adoptive cellular immunotherapy in which a patient’s T cells are collected, commonly by leukapheresis, and genetically modified to express a chimeric antigen receptor (CAR). The CAR combines an antigen-binding domain with intracellular signaling components, enabling CAR-T cells to recognize selected surface antigens independently of conventional antigen presentation and to activate cytotoxic and immune-effector responses against antigen-bearing cells. CAR constructs may differ in their costimulatory domains and spacer design; the ENCIT01 trial, for example, compares second- and third-generation L1CAM-specific CAR-T cells in neuroblastoma.
Clinically, CAR-T therapy is used primarily as an immune effector treatment for relapsed or refractory hematologic malignancies, including multiple myeloma and selected lymphomas, where outcomes are assessed by remission, relapse, progression, progression-free survival, and mortality. Targets and applications continue to expand: BCMA-directed CAR-T therapy has been investigated in refractory primary immune thrombocytopenia, while studies are also examining treatment for central nervous system lymphomas and myeloma with central nervous system involvement. Important toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, with ongoing research addressing neurologic, cognitive, cardiovascular, and longer-term outcomes. CAR-T therapy is also being evaluated alongside or sequentially with bispecific antibodies, and decentralized or hospital-based manufacturing approaches seek to improve its accessibility and cost-effectiveness.
Where the papers sit
8 papers from the last 6 months study Chimeric Antigen Receptor T-cell therapy directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 4 observational · 3 human data
Themes 3 themes
-
Relapsed Myeloma Treatment
CAR T-cell therapy and bispecific antibodies are being weighed as single or sequential treatments for relapsed/refractory multiple myeloma. Progression and therapeutic response remain central, with the optimal order and patient selection unresolved. Central nervous system involvement adds a high-risk clinical course that may complicate treatment choice. Economic work is also moving toward AI-supported, hospital-based CAR T production as a way to improve access and cost-effectiveness.
4 papers · 50%
-
CAR-T Safety and Outcomes
CAR-T outcome research is widening from remission to cardiovascular, neurologic, and cognitive safety. Cytokine release syndrome and neurotoxicity remain recurring concerns, while Montreal Cognitive Assessment results address medium-term function after treatment for CNS lymphoma. Medicare data quantify cardiovascular outcomes at population scale. The ENCIT01 trial tests whether third-generation L1CAM-specific CAR T cells improve on second-generation cells in primary refractory CNS lymphoma.
3 papers · 37.5%
-
CAR-T for Immune Thrombocytopenia
BCMA-directed CAR T-cell therapy is being tested as a way to reset refractory primary immune thrombocytopenia. The reported pattern combines platelet recovery with durable drug-free remission, rather than continuing immune-directed medication. Thrombocytopenia and immune thrombocytopenia define the clinical endpoint, with B-cell Maturation Antigen providing the target. Durability, safety, and reproducibility beyond this early evidence remain open questions.
1 papers · 12.5%
Papers
The 8 papers from the last 6 months that study Chimeric Antigen Receptor T-cell therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Relapsed Myeloma Treatment (4)
- Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR cancer · 13 Oct 2026 PMID 42868529
- Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma. Blood cancer discovery · 13 Aug 2026 PMID 42593166
- Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement. Blood advances · 25 Jun 2026 PMID 42348786
- Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. Blood cancer discovery · 12 Jun 2026 PMID 42284467
CAR-T Safety and Outcomes (3)
- Medium-Term Cognitive Outcome in Patients With CNS Lymphomas Treated With Chimeric Antigen Receptor T-Cell Therapy. Neurology · 2 Oct 2026 PMID 42826379
- The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 Jun 2026 PMID 42312971
- Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. European heart journal · 27 May 2026 PMID 42199067
CAR-T for Immune Thrombocytopenia (1)
- BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia. Blood · 24 Jul 2026 PMID 42498681
By study type
Clinical trials (1)
- The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 Jun 2026 PMID 42312971
Observational studies and case reports (4)
- Medium-Term Cognitive Outcome in Patients With CNS Lymphomas Treated With Chimeric Antigen Receptor T-Cell Therapy. Neurology · 2 Oct 2026 PMID 42826379
- Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement. Blood advances · 25 Jun 2026 PMID 42348786
- Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. Blood cancer discovery · 12 Jun 2026 PMID 42284467
- Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. European heart journal · 27 May 2026 PMID 42199067
Human data, design not indexed (3)
- Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR cancer · 13 Oct 2026 PMID 42868529
- Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma. Blood cancer discovery · 13 Aug 2026 PMID 42593166
- BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia. Blood · 24 Jul 2026 PMID 42498681
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-10-31. Drafted by language models from published abstracts; not medical advice.